Antimicrobial and Antibiofilm Activity of Secondary Metabolites of Lichens against Methicillin-Resistant<i>Staphylococcus Aureus</i>Strains from Cystic Fibrosis Patients

Abstract

Secondary metabolites of lichens may be considered to be 'lead compounds' for the development of novel molecules for the treatment of S. aureus infections in cystic fibrosis patients.